|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Institute of Cancer Research, United Kingdom |
|---|---|
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00031850 |
Purpose
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of raloxifene and goserelin may be effective in preventing breast cancer.
PURPOSE: Randomized pilot study to study the effectiveness of combining raloxifene and goserelin in preventing breast cancer in women who have a family history of breast cancer.
| Condition | Intervention |
|---|---|
|
Breast Cancer |
Drug: goserelin Drug: raloxifene |
| Study Type: | Interventional |
| Study Design: | Prevention |
| Official Title: | A Randomized Trial Of Raloxifene Plus Zoladex For Prevention Of Breast Cancer |
| Estimated Enrollment: | 150 |
| Study Start Date: | March 2000 |
OBJECTIVES:
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center. Patients are randomized to one of two treatment arms.
Quality of life is assessed at baseline and at 1, 3, 6, and 12 months.
Patients are followed for 5 years.
PROJECTED ACCRUAL: A total of 150 patients (75 per treatment arm) will be accrued for this study.
Eligibility| Ages Eligible for Study: | 30 Years to 45 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
High genetic risk of developing breast cancer defined as one or more of the following:
No evidence of breast cancer by mammography
Hormone receptor status:
PATIENT CHARACTERISTICS:
Age:
Sex:
Menopausal status:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Pulmonary:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
Contacts and Locations| United Kingdom, England | |
| Christie Hospital NHS Trust | |
| Manchester, England, United Kingdom, M20 4BX | |
| Study Chair: | Anthony Howell, MD | Christie Hospital NHS Foundation Trust |
More Information
| Study ID Numbers: | CDR0000069233, NCRI-IBIS-RAZOR, EU-20053, UKCCCR-IBIS-RAZOR, ISRCTN17775670 |
| Study First Received: | March 8, 2002 |
| Last Updated: | May 23, 2008 |
| ClinicalTrials.gov Identifier: | NCT00031850 History of Changes |
| Health Authority: | United States: Federal Government |
|
breast cancer |
|
Estrogen Antagonists Estrogens Skin Diseases Antineoplastic Agents, Hormonal Hormone Antagonists Goserelin Hormones, Hormone Substitutes, and Hormone Antagonists |
Breast Neoplasms Bone Density Conservation Agents Selective Estrogen Receptor Modulators Hormones Estrogen Receptor Modulators Raloxifene Breast Diseases |
|
Estrogen Antagonists Skin Diseases Antineoplastic Agents, Hormonal Antineoplastic Agents Hormone Antagonists Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Goserelin Breast Neoplasms |
Bone Density Conservation Agents Selective Estrogen Receptor Modulators Pharmacologic Actions Estrogen Receptor Modulators Neoplasms Raloxifene Neoplasms by Site Therapeutic Uses Breast Diseases |